You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-20 of 119 results found

A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences

Recent research has demonstrated that neoantigen-specific T-cell receptors (TCRs) can be isolated from a cancer patient’s lymphocytes. These TCRs may be used to engineer populations of tumor-reactive T cells for cancer immunotherapies. Obtaining sequences of these functional TCRs is a critical initial step in preparing this type of personalized cancer treatment; however, current methods are time-consuming and labor-intensive. Scientists at the National Cancer Institute (NCI) have developed a rapid and robust method of isolating the sequences of mutation-specific TCRs to alleviate these issues; they seek licensing and/or co-development research collaborations for the development of a method for isolating the sequences of tumor-reactive TCRs. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D. at sar@nih.gov.
  • Research Tools
  • Therapeutics

Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine

To date, there is no FDA-approved therapeutic vaccine for human papillomavirus (HPV). Researchers at the National Cancer Institute (NCI) have discovered agonist epitopes for the development of an HPV therapeutic vaccine. NCI is seeking parties interested in licensing and/or co-developing HPV agonist epitopes that enhance the activation of cytotoxic T lymphocytes (CTL) and lysis of human tumor cells.
  • Therapeutics

Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)

The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment.
  • Therapeutics

Analogues of Withanolide E Sensitize Cancer Cells Toward Apoptosis

There is a need to develop compounds that can sensitize cancer cells to apoptosis inducing ligands, such as poly I:C and TRAIL. In collaboration with the University of Arizona, NCI investigators discovered a series of compounds in the withanolide family that synergistically enhance the response of cancer cells to treatment with an apoptosis-inducing ligand. The NCI seeks licensing and/or co-development research collaborations for development of withanolide E analogues for the treatment of cancer.
  • Therapeutics

Angiogenesis-Based Cancer Therapeutic

The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.
  • Therapeutics

Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma

Chimeric antigen receptor (CAR) T cells that specifically target Glypican 2 (GPC2) are strong therapeutic candidates for patients with neuroblastoma and other GPC2-expressing cancers. The inventors at the National Cancer Institute (NCI) have developed a potent anti-GPC2 (CT3) CAR containing CD28 hinge and transmembrane domains (CT3.28H.BBζ) that is available for licensing and co-development.
  • Therapeutics

Anti-SLAMF7 Chimeric Antigen Receptors

Chimeric Antigen Receptor T cell (CAR-T) therapies that specifically target Signaling Lymphocyte Activation Molecule F7 (SLAMF7) are strong therapeutic candidates for patients with Multiple Myeloma (MM). SLAMF7 is highly expressed on the malignant plasma cells that constitute MM. The expression of SLAMF7 by MM cells and lack of expression on nonhematologic cells makes SLAMF7 an attractive therapeutic target for MM. Researchers at the National Cancer Institute (NCI) have invented anti- SLAMF7 CAR constructs that allow genetically-modified T cells to express both the anti-SLAMF7 antibody and a suicide gene that allows T cells to specifically recognize and kill SLAMF7-expressing cells as well as allow for on-demand and reliable elimination of anti-SLAMF7 CAR T cells. NCI seeks licensing and/or co-development partners for this invention.
  • Therapeutics

Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers

The National Cancer Institute Laboratory of Molecular Biology is seeking statements of capability or interest from parties interested in licensing or collaborative research to further develop, evaluate, or commercialize antibody-based treatments of mesothelin-expressing cancers.
  • Therapeutics

Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment

Researchers at the National Cancer Institute (NCI) have developed aryl hydantoin heterocycles that target the androgen receptor (AR). NCI seeks research co-development partners and/or licensees to develop these compounds as therapeutics for prostate cancer. As these compounds consist of both AR agonists and antagonists, they may also be effective therapeutics for androgen dysfunctional disorders, such as androgen deficiency disorders or hyperandrogenism.
  • Therapeutics

Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer

Researchers at the National Cancer Institute (NCI) have discovered that primary bile acids and antibiotics are a novel therapeutic for the treatment of liver cancer and liver metastases. NCI is seeking parties interested in licensing and/or co-developing primary bile acids and antibiotics that have been demonstrated in vivo to attract natural killer T (NKT) cells to the liver and inhibit tumor development.
  • Therapeutics

Brachyury-directed Vaccine for the Prevention or Treatment of Cancers

Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Stimulation of T cells with the Brachyury peptide promote a robust immune response and lead to targeted lysis of invasive tumor cells. NCI seeks licensing or co-development of this invention.
  • Therapeutics
  • Vaccines

Cancer Immunotherapy Using Virus-like Particles

A considerable effort has been devoted to identifying and targeting specific extracellular cancer markers using antibody based therapies. However, diminished access to new cancer cell surface markers has limited the development of corresponding antibodies. NCI Technology Transfer Center is seeking to license cancer immunotherapy using virus-like particles.
  • Therapeutics

Cancer Inhibitors Isolated from an African Plant

The National Cancer Institute's Molecular Targets Development Program is seeking parties interested in collaborative research to further develop, evaluate, or commercialize cancer inhibitors isolated from the African plant Phyllanthus englerii. The technology is also available for exclusive or non-exclusive licensing.
  • Therapeutics

Pages